Between the second-generation CAR T cell variants, IL13-BBζ again outperformed IL13-28ζ CAR T cells, with more efficient tumor elimination and CAR T cell proliferation following repetitive tumor addition (Fig 2D). This evidence concerns the gene IL13 and neoplasm.